A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthmatic patients
Latest Information Update: 09 May 2022
At a glance
- Drugs Indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis
- 28 Jun 2012 Planned number of patients changed from 24 to 28 as reported by European Clinical Trials Database record.
- 01 Sep 2010 Actual patient number is 28 as reported by ClinicalTrials.gov.
- 21 Jul 2008 Actual completion date identified as Apr 2008, as reported by ClinicalTrials.gov.